BeOne Medicines Ltd. - American Depositary Shares (ONC)

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress.

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff.

BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.